BioNeutral Has Retained DC-Based Law Firm Hogan & Hartson to Manage Its EPA/FDA Regulatory Process
NEWARK, N.J.-(Business Wire)-September 3, 2009 - BioNeutral Group, Inc. (OTCBB: BONU) has retained Hogan and Hartson, one of Washington’s oldest and most prestigious law firms, to manage its regulatory affairs as it proceeds through the approval process for its technology. Patrick Raher, a senior partner and the chairman of Hogan & Hartson’s environmental practice, will serve as lead counsel for the BioNeutral Group.
BioNeutral is a publicly traded specialty life science company that is developing several product lines intended to neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses and spores. Some of its product applications (hard and soft surface sterilants and disinfectancts) will require certification by the Environmental Protection Agency (EPA); others (wound care, acne, sterilization of medical/surgical/dental instruments) will require approval by the Food and Drug Administration (FDA). Other product applications in the pipeline, such as stain removers, cleaners, and rust inhibitors are not regulated. Hogan & Hartson has decades of experience in helping clients achieve efficient certification and approvals in the Federal and state regulatory process.
With more than 1,100 lawyers practicing in 27 offices worldwide, Hogan & Hartson brings multiple practices and offices to bear to provide its clients with exceptional service and creative advice. Working at the intersection of business and government, both domestically and internationally, the firm helps its clients structure and complete their projects and transactions and guides them through the maze of government regulation. The firm also has special expertise in securing, protecting, and defending their clients’ intellectual property.
“I have great confidence in Mr. Raher’s and his team’s professional ability,” said Dr. Jeffrey Runge of Washington’s Chertoff Group and BioNeutral’s senior medical advisor. “As the former head of the National Highway Traffic Safety Administration, I had the opportunity to witness his firm’s ability from the perspective of a Federal regulator. They have the highest integrity and clearly understand the regulatory process.”
“We are extremely pleased to have this highly experienced and prestigious law firm join our group of platinum advisors to assist us in navigating the complexities of the regulatory process. This move will consolidate our various product registrations and is a key component to our overall business strategy,” stated Stephen J. Browand, President & CEO of BioNeutral.
ABOUT BIONEUTRAL GROUP
Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene and Ogiene, which are eco-friendly and include natural and common ingredients found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers.
BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications.
More information about the Company may be found at www.bioneutralgroup.com.
FORWARD LOOKING STATEMENTS
BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene and are not yet available for sale in the United States.
Under the Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes”, and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of BioNeutral Group can be found in the filings of BioNeutral Group with the U.S. Securities and Exchange Commission.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
